If you're on semaglutide or tirzepatide and losing more hair than you'd like, you've probably looked into biotin supplements. Most people do. Hair loss is one of the most commonly reported experiences during the first few months on a GLP-1 medication, the leading hair supplements prominently feature biotin, and it's available everywhere without a prescription. Reaching for one makes complete sense.
What most people — and most of their doctors — don't know is that the doses in those supplements can interfere with blood tests that GLP-1 patients have regularly. The FDA has issued two formal warnings about this. The problem isn't biotin itself. It's the dose.
Why hair loss happens on a GLP-1
The shedding most GLP-1 patients experience is called telogen effluvium. Hair follicles are among the most metabolically demanding tissue in the body, and when caloric intake drops sharply — as it does on semaglutide and tirzepatide — the follicle responds by entering a resting phase. The drug isn't directly damaging the follicle. The metabolic stress of rapid weight loss is triggering a temporary shift in the hair growth cycle. Shedding typically peaks at months three to six and is self-limiting for most people.
Because biotin plays a role in keratin production — the protein that forms the hair shaft — it has become the go-to ingredient in supplements marketed for hair. That association is real at a basic metabolic level. The question is how much biotin is actually needed, and whether the doses in leading supplements create problems elsewhere. For the broader picture of how GLP-1 therapy changes skin, hair, and tissue at the cellular level, see Why Your Skin Changes on GLP-1.
What the FDA found
In November 2017, the FDA issued a safety communication warning that high-dose biotin supplements had caused a falsely low troponin result in a patient being evaluated for a heart attack, leading to incorrect treatment.[1] In November 2019, the FDA updated that warning, confirming that the interference extended to a broad range of blood tests: thyroid function panels, ferritin, hormone levels, and others.[2]
The mechanism is specific. Many standard laboratory tests use a chemical process called biotin-streptavidin binding as part of their architecture. When a patient has elevated biotin circulating in their blood from supplementation, that excess biotin competes with the test reagents and distorts the result — producing readings that are falsely high or falsely low depending on the specific test. At the levels found in food and in low-dose supplements, this doesn't happen. At the megadoses found in most hair supplements, it does.
Why your doctor probably hasn't mentioned this
This isn't a gap anyone should feel bad about. It's a structural one.
Your GLP-1 prescriber — most likely a primary care physician, internist, or endocrinologist — is focused on your metabolic health, your glucose response, your cardiovascular risk, and your weight trajectory. Supplement-lab interactions for hair loss aren't typically on that checklist. The prescriber ordering your TSH and ferritin panels may not know you've started a hair supplement on your own.
On the dermatology side, the picture isn't much cleaner. Shari Lipner, MD, PhD, a dermatologist at Weill Cornell Medicine who has been one of the most vocal researchers on this issue, laid out just how little the 2017 warning changed clinical practice in a 2020 review:[6] a survey of 113 dermatologists found 51% were still prescribing biotin two years after the FDA's warning.[7] The same review reported that of 119 biotin articles published in the two years following the warning, only 21% cited biotin's risks and only 5% mentioned the FDA warning at all.[5] The warning simply didn't travel well through clinical channels.
More recently, Brittany Dulmage, MD, an oncodermatologist at The Ohio State University Comprehensive Cancer Center, published research in JCO Oncology Practice on the same issue in cancer patients — another monitored population who frequently reach for biotin during treatment-related hair loss.[8] Her clinical observation: more than half of patients who came to her with a hair loss concern had self-started a biotin supplement, often without telling their care team. "People have the misconception that biotin supplements are harmless and there's no reason not to take them," she said. "The reality is that the supplements may cause inaccurate lab results, resulting in a delay or change in patients' treatment plans."
The parallel to GLP-1 patients is direct. Both populations are on long-term therapy, have regular blood draws, experience hair loss that prompts supplement-seeking, and are unlikely to have had a conversation with their prescriber specifically about biotin interference.
Which tests are affected — and why they matter for GLP-1 patients
The American Association for Clinical Chemistry has established in formal laboratory guidance that biotin in standard multivitamins — doses up to 1,000 mcg — has not been reported to cause immunoassay interference. At 5,000 mcg or above, interference with commonly used biotinylated immunoassays is documented.[9]
The tests most relevant to people on GLP-1 therapy:
- Thyroid function (TSH and free thyroid hormones). Routine monitoring for GLP-1 patients, particularly those on tirzepatide given the class labeling around thyroid C-cell tumors. Biotin interference can produce falsely suppressed or falsely elevated TSH — a result that looks real and may prompt unnecessary follow-up or miss a genuine finding.
- Ferritin. GLP-1 therapy is associated with meaningful iron depletion — a large cohort study of more than 461,000 patients found ferritin levels 26–30% lower in GLP-1 users relative to comparators.[3] Ferritin is the primary marker for iron stores. Biotin interference can produce a falsely elevated ferritin, masking a real deficit at exactly the time that deficit is most likely to exist.
- Cardiac troponin. The original 2017 FDA warning documented a life-threatening misread. This remains the most serious documented consequence on record.
- Vitamin D. Commonly monitored in GLP-1 patients given high rates of insufficiency in this population.
The overlap between what biotin disrupts and what GLP-1 patients have measured regularly is nearly complete.
What's in leading hair supplements
Nutrafol is the #1 dermatologist-recommended hair supplement brand in the United States, according to the IQVIA ProVoice survey for the 12 months ending March 2026. Its core women's and men's formulas contain 3,000 micrograms of biotin per serving — 10,000% of the Daily Value. A 2025 case report in JAAD Case Reports examined a patient who developed vitamin D toxicity while using this same product, and in documenting the product's full ingredient profile, also noted its 3,000 mcg biotin dose — a useful independent confirmation of what's actually in a leading formula.[10]
Nutrafol is not unusual in this regard. High-dose biotin is standard across the category. Most patients choosing a hair supplement have no reason to think the dose is anything other than a feature.
What you can do about it
The good news is that this is a manageable problem once you know about it.
Tell your GLP-1 prescriber you're taking or considering a biotin supplement, and what dose. This matters specifically before any scheduled blood draw. Many laboratories have biotin-tolerant assay methods available, but they need to know to use them. Dulmage advises patients who choose to continue biotin to stop at least 72 hours before any scheduled blood work — enough time for supplemental biotin to clear to levels that don't affect most assays.
If you're evaluating supplements, look at the biotin dose on the label. The Recommended Dietary Allowance for biotin in adults is 30 micrograms per day. Supplementing at 300 micrograms — ten times the RDA, well within the range that supports follicle metabolism — provides the metabolic support biotin is known for without approaching the interference threshold documented in laboratory guidance. A supplement designed with GLP-1 patients in mind should account for the fact that GLP-1 patients have regular blood draws. The biotin dose is where that consideration shows up on the label.
The bottom line
Hair loss on a GLP-1 medication is real, common, and driven by the metabolic stress of rapid weight loss rather than the drug itself. Reaching for a hair supplement is a natural response. What most patients — and many of their doctors — don't know is that the doses in leading hair supplements can interfere with the blood tests a GLP-1 patient has regularly, including thyroid panels, ferritin, and cardiac markers. The FDA documented this risk in 2017 and reiterated it in 2019.
You're likely navigating this across providers who aren't coordinating on it. Knowing what's in your supplements, telling your prescriber before labs, and paying attention to the biotin dose on any label you're considering are the practical steps that close the gap. For a full list of the peer-reviewed sources behind this article, see the Pellvara references hub.
Pellvara is building a skin and nutrition system formulated specifically for GLP-1 patients — including a supplement with a GLP-1-appropriate biotin dose. Join the early access list →